Lipoprotein and Apolipoproteins With Metabolic Liver Diseases

Chun-Hsiang Wang

Status: Unknown

Conditions: Disorders of Lipoprotein Metabolism and Other Lipidaemias

Treatments: Other: lipoprotein and apolipoproteins

Study type: Observational

Funder types: Other

Identifiers

NCT03220971

1060603

Details and patient eligibility

About

Theranostic translation applications against viral, metabolic liver diseases and hepatic oncogenesis: lipoprotein and apolipoproteins at a crossroad

Full description

An intimate link between microbial infections, metabolic changes and oncogenesis has been drawn attentions increasingly, indicating a crossroad leading to pathogenesis and disease progression. Globally the burden of hepatitis B and C virus infections is 450 and 185 millions, respectively and chronic hepatitis disease causes a high risk of liver cirrhosis, hepatocellular carcinoma and metabolic disorders

Enrollment: 440 estimated patients

Sex: All

Ages: 20 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. above 20 years
2. nonalcoholic fatty liver disease
3. Non-Alcoholic Steatohepatitis

Exclusion criteria

1. alcohonic hepatitis 2. Autoimmune liver disease 3. HIV postive

Trial design

440 participants in 2 patient groups

proposed cross-section study

Description:

1. 100 subjects with NAFLD/NASH and negative anti-HCV Ab 2. 50 subjects with HCC and negative anti-HCV Ab 3. 50 subjects with HCC and positive for genotype-1 HCV 4. 50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV 5. 50 controls with all negative for NAFL, NASH and HCV

Treatment:

Other: lipoprotein and apolipoproteins

proposed longitudinal study

Description:

1. 50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR 2. 10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR 3. 10 HCC patients and positive for genotype-1 HCV with SVR 4. 10 HCC patients and positive for genotype-1 HCV without SVR 5. 50 chronic hepatitis C but not NAFLD patients with SVR 6. 10 chronic hepatitis C but not NAFLD patients without SVR

Treatment:

Other: lipoprotein and apolipoproteins